TITLE

CUMBERLAND/ALVEDA TO COMMERCIALIZE CALDOR IN CANADA

PUB. DATE
June 2010
SOURCE
Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the exclusive agreement signed by Cumberland Pharmaceuticals Inc. with Alveda Pharmaceuticals Inc. to commercialize the Caldolor Injection in Canada in June 2010. It says that Caldolor is designed to treat fever and pain in hospitals, which was approved by the Food and Drug Administration (FDA) in the U.S. and launched by Cumberland in 2009. Cumberland chief executive officer A. J. Kazimi says that the company is pleased to make Alveda Pharma a part of its network of international partners. The terms of the deal are also explained.
ACCESSION #
51161377

 

Related Articles

  • Pain.  // PharmaWatch: CNS;Jul2009, Vol. 8 Issue 7, p21 

    The article offers updates related to pain remedy drugs. Caraco Pharmaceutical Laboratories Ltd. has launched oxycodone hydrochloride tablets indicated for the management of moderate to severe pain. The supplemental new drug application for Cymbalta for the management of chronic pain was...

  • Caldolor for pain & fever.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA7 

    The article reports on the development of intravenous ibuprofen Caldolor by Cumberland Pharmaceuticals Inc. used to treat pain and fever. It mentions that the drug is used to manage mild to moderate pain and moderate to severe pain as an alternative to opioid analgesics. It also states that the...

  • PAIN DRUGS: A DIVERSE FIELD.  // Applied Clinical Trials;Oct2010, Vol. 19 Issue 10, p16 

    The article offers news briefs related to clinical trials of analgesics. Transdel Pharmaceuticals Inc. has announced positive Phase III data for its transdermal non-steroidal anti-inflammatory drug Ketotransdel. Cumberland Pharmaceuticals Inc. has published data supporting the safety of Caldolor...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Aug2009 Pharmacology Watch, p2 

    The article reports on the actions taken by the U.S. Food & Drug Administration (FDA). FDA warned consumers about the adverse effect of three Zicam® products, namely Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Nasal Swabs, and Zicam Cold Remedy Swabs Kids Sized. Such products are said to...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Aug2009 Supplement, p2 

    The article reports on the actions taken by the U.S. Food & Drug Administration (FDA). FDA warned consumers about the adverse effect of three Zicam® products, namely Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Nasal Swabs, and Zicam Cold Remedy Swabs Kids Sized. Such products are said to...

  • FDA Actions.  // Infectious Disease Alert;Aug2009 Supplement, p2 

    The article reports on the actions of the Food and Drug Administration (FDA) in the U.S. According to the FDA, Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Nasal Swabs and Zicam Cold Remedy Swabs Kids Sized may cause anosmia or permanent loss of smell. Approval has been given by the agency for...

  • FDA draft guidance on developing analgesic drug/biological products.  // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p8 

    The article reports that a draft guidance, titled "Analgesic Indications: Developing Drug and Biological Products," has been released by the U.S. Food & Drug Administration (FDA), which focuses on the development of prescription drugs for the management of acute and chronic pain.

  • A non-narcotic boasts narcotic strength. Cerrato, Paul L. // RN;Feb98, Vol. 61 Issue 2, p70 

    Presents information on Bromfenac (Duract), a nonnarcotic analgesic which was proven effective as oxycodone/acetaminophen (Percocet) and approved by the United States Food and Drug Administration for relieving acute pain. Information on Bromfenac; Complications of this drug.

  • QbD impact minimal so far.  // Pharmaceutical Technology;Aug2010 Supplement, ps14 

    The article focuses on the impact of the U.S. Food and Drug Administration's quality-by-design (QbD) initiative on the nature of the work being requested of and performed by contract development organizations.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics